Tvardi Therapeutics (LTS:0HTC) Market Cap: £13.50 Mil (As of Jul. 01, 2026)


What is Tvardi Therapeutics Market Cap?

Tvardi Therapeutics LTS:0HTC 12 Market Cap is £13.50 Mil as of Jul. 01, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,427 Biotechnology companies, Tvardi Therapeutics ranks worse than 77.51% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Tvardi Therapeutics's share price for the quarter that ended in Mar. 2026 was £0. Tvardi Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 9.38 Mil. Therefore, Tvardi Therapeutics's market cap for the quarter that ended in Mar. 2026 was £0.00 Mil.

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tvardi Therapeutics's Enterprise Value for Today is £0.00 Mil.

Tvardi Therapeutics  (LTS:0HTC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Tvardi Therapeutics Market Cap Related Terms

Tvardi Therapeutics Market Cap Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Market Cap Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Market Cap
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTC vs HOWL, TPST, XCUR: Market Cap Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Market Cap falls into.


Tvardi Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Tvardi Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=£0*9.381
=£0.00

Tvardi Therapeutics's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=£0*9.381
=£0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of £13.50 Mil mean?
Tvardi Therapeutics (LTS:0HTC) has a Market Cap of £13.50 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #1106 out of 1427 companies in the Biotechnology industry, placing it in the top 77.5%.
Is Tvardi Therapeutics' Market Cap too high?
Tvardi Therapeutics' current Market Cap is £13.50 Mil. Based on the distribution chart, Tvardi Therapeutics ranks #1106 out of 1427 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Market Cap compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #1106 out of 1427 companies for Market Cap. This places Tvardi Therapeutics in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current Market Cap is £13.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Market Cap of £13.50 Mil. The current Market Cap is £13.50 Mil. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Market Cap is £13.50 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.